These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 37775737

  • 1. Predictive factors for survival in borderline resectable and locally advanced pancreatic cancer: are these really two different entities?
    de Carvalho LFA, Gryspeerdt F, Rashidian N, Van Hove K, Maertens L, Ribeiro S, Hoorens A, Berrevoet F.
    BMC Surg; 2023 Sep 30; 23(1):296. PubMed ID: 37775737
    [Abstract] [Full Text] [Related]

  • 2. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T, Pergolini I, Castillo CF, Honselmann KC, Cai L, Deshpande V, Wo JY, Ryan DP, Allen JN, Blaszkowsky LS, Clark JW, Murphy JE, Nipp RD, Parikh A, Qadan M, Warshaw AL, Hong TS, Lillemoe KD, Ferrone CR.
    Ann Surg; 2019 Apr 30; 269(4):733-740. PubMed ID: 29227344
    [Abstract] [Full Text] [Related]

  • 3. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
    Harrison JM, Wo JY, Ferrone CR, Horick NK, Keane FK, Qadan M, Lillemoe KD, Hong TS, Clark JW, Blaszkowsky LS, Allen JN, Castillo CF.
    Ann Surg Oncol; 2020 May 30; 27(5):1400-1406. PubMed ID: 31758284
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M, Antunes C, Pietrasz D, Cassinotto C, Zappa M, Sa Cunha A, Lucidarme O, Bachet JB.
    Eur Radiol; 2017 Jul 30; 27(7):3104-3116. PubMed ID: 27896469
    [Abstract] [Full Text] [Related]

  • 11. Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma.
    Temraz S, Nassar F, Hammoud MS, Mukherji D, O'Reilly EM, Dbouk H, Farhat F, Charafeddine M, Faraj W, Khalifeh MJ, Abou-Alfa GK, Shamseddine A.
    Asia Pac J Clin Oncol; 2022 Dec 30; 18(6):735-742. PubMed ID: 35362216
    [Abstract] [Full Text] [Related]

  • 12. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
    Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, Clark JW, Faris JE, Goyal L, Kwak EL, Murphy JE, Ting DT, Wo JY, Zhu AX, Warshaw AL, Lillemoe KD, Fernández-del Castillo C.
    Ann Surg; 2015 Jan 30; 261(1):12-7. PubMed ID: 25599322
    [Abstract] [Full Text] [Related]

  • 13. Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis.
    Lindemann J, du Toit L, Kotze U, Bernon M, Krige J, Jonas E.
    HPB (Oxford); 2021 Feb 30; 23(2):173-186. PubMed ID: 33268268
    [Abstract] [Full Text] [Related]

  • 14. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer.
    Kang JH, Lee SS, Kim JH, Byun JH, Kim HJ, Yoo C, Kim KP, Ryoo BY, Kim SC.
    Eur Radiol; 2021 Feb 30; 31(2):864-874. PubMed ID: 32813104
    [Abstract] [Full Text] [Related]

  • 15. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
    Nitsche U, Wenzel P, Siveke JT, Braren R, Holzapfel K, Schlitter AM, Stöß C, Kong B, Esposito I, Erkan M, Michalski CW, Friess H, Kleeff J.
    Ann Surg Oncol; 2015 Dec 30; 22 Suppl 3():S1212-20. PubMed ID: 26350368
    [Abstract] [Full Text] [Related]

  • 16. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study.
    Janssen QP, van Dam JL, Prakash LR, Doppenberg D, Crane CH, van Eijck CHJ, Ellsworth SG, Jarnagin WR, O'Reilly EM, Paniccia A, Reyngold M, Besselink MG, Katz MHG, Tzeng CD, Zureikat AH, Groot Koerkamp B, Wei AC, Trans-Atlantic Pancreatic Surgery (TAPS) Consortium.
    J Natl Compr Canc Netw; 2022 Jul 30; 20(7):783-791.e1. PubMed ID: 35830887
    [Abstract] [Full Text] [Related]

  • 17. CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer.
    Williams JL, Kadera BE, Nguyen AH, Muthusamy VR, Wainberg ZA, Hines OJ, Reber HA, Donahue TR.
    J Gastrointest Surg; 2016 Jul 30; 20(7):1331-42. PubMed ID: 27114246
    [Abstract] [Full Text] [Related]

  • 18. Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer.
    Alva-Ruiz R, Yohanathan L, Yonkus JA, Abdelrahman AM, Gregory LA, Halfdanarson TR, Mahipal A, McWilliams RR, Ma WW, Hallemeier CL, Graham RP, Grotz TE, Smoot RL, Cleary SP, Nagorney DM, Kendrick ML, Truty MJ.
    Ann Surg Oncol; 2022 Mar 30; 29(3):1579-1591. PubMed ID: 34724125
    [Abstract] [Full Text] [Related]

  • 19. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Maggino L, Malleo G, Marchegiani G, Viviani E, Nessi C, Ciprani D, Esposito A, Landoni L, Casetti L, Tuveri M, Paiella S, Casciani F, Sereni E, Binco A, Bonamini D, Secchettin E, Auriemma A, Merz V, Simionato F, Zecchetto C, D'Onofrio M, Melisi D, Bassi C, Salvia R.
    JAMA Surg; 2019 Oct 01; 154(10):932-942. PubMed ID: 31339530
    [Abstract] [Full Text] [Related]

  • 20. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
    Asari S, Matsumoto I, Toyama H, Shinzeki M, Goto T, Ishida J, Ajiki T, Fukumoto T, Ku Y.
    Surg Today; 2016 May 01; 46(5):583-92. PubMed ID: 26108488
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.